Articles tagged "Outcome"

2019 American Transplant Congress
Evaluating Hepatitis C Treatment after Solid Organ Transplantation
A. J. Burgos¹, R. Yau¹, C. Tunwar², J. A. Goss³, S. Khaderi³, N. L. Sussman⁴
¹Pharmacy, CHI St. Luke's Health-Baylor St. Luke's Medical Center, Houston, TX, ²CHI St. Luke's Health-Baylor St. Luke's Medical Center, Houston, TX, ³Division of Abdominal Transplantation, Baylor College of Medicine, Houston, TX, ⁴Abdominal Transplant & Liver Disease, Baylor College of Medicine, Houston, TX
*Purpose: There is limited data on the use of direct acting antivirals for hepatitis C virus (HCV) in the solid organ transplant (SOT) population. The…
2019 American Transplant Congress
Breaking Concepts: 10-year Follow-Up of the Everolimus versus Azathioprine Heart Transplant Multi-National Study
J. A. Kobashigawa¹, R. Starling², E. Passano¹, P. Bernhardt³, B. Azarbal¹, R. Cheng¹, F. Esmailian¹, K. Khush⁴, D. Mancini⁵, J. Patel¹, T. Sato¹, S. Varnous⁶
¹Smidt Heart Institute at Cedars-Sinai, Los Angeles, CA, ²Cleveland Clinic, Cleveland, OH, ³Novartis Pharmaceuticals, Basel, Switzerland, ⁴Stanford University, Palo Alto, CA, ⁵Mount Sinai, New York, NY, ⁶APHP, Pitié‐Salpétrière, Sorbonne University, Paris, France
*Purpose: This study is the 10-year follow-up of a randomized double-blind prospective trial that compared everolimus (1.5 mg or 3 mg) to azathioprine. In this…
2019 American Transplant Congress
Transplantation of Kidneys from Hepatitis C Infected Donors to Hepatitis C Negative Recipients
M. Z. Molnar, O. Cseprekal, M. Yazawa, M. Talwar, V. Balaraman, V. Mas, D. Maluf, R. Helmick, L. Campos, N. Nezakatgoo, C. Eymard, P. Horton, R. Verma, A. Jenkins, C. R. Handley, H. Snyder, C. Cummings, U. A. Agbim, B. Maliakkal, S. K. Satapathy, S. P. Nair, J. D. Eason
Methodist University Hospital Transplant Institute, Memphis, TN
*Purpose: There are no data on the safety of kidney transplantation from hepatitis C (HCV) NAT positive donors to HCV naïve recipients. We report the…
2019 American Transplant Congress
Impact Of Cold And Warm Ischemia Time On Outcomes For Kidneys Donated After Cardiac Death
C. Brennan¹, P. R. Sandoval², S. A. Husain², D. Tsapepas¹, S. Mohan², L. E. Ratner²
¹New York Presbyterian, New York, NY, ²Columbia University Medical Center, New York, NY
*Purpose: Donors after cardiac death (DCD) organs are frequently being discarded. Prolonged warm (WIT) cold (CIT) ischemia times are often important considerations in the discard…
2019 American Transplant Congress
Actions Speak Louder Than Labs – The Impact of Dialysis Compliance on Posttransplant Outcomes
D. Sawinski¹, H. Lindner², J. Schults³, J. Locke⁴, P. Reese¹
¹Hospital of the U of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Children's Hospital of Pennsylvania, Philadelphia, PA, ⁴University of Alabama at Birmingham, Birmingham, AL
*Purpose: Non-adherence is a modifable risk factor for poor posttransplant outcomes. While the factors contributing to posttransplant non-adherence are complex, noncompliance with the dialysis prescription…
2019 American Transplant Congress
The Use of Native Kidney Biopsy to Predict Renal Dysfunction Following Liver Transplantation
D. O. Walls¹, L. Muraveika¹, M. B. Palmer², D. L. Sawinski³, B. J. Keating¹, P. L. Abt¹
¹Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, ²Pathology, Hospital of the University of Pennsylvania, Philadelphia, PA, ³Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA
*Purpose: Acute and chronic kidney injury are a common occurrence for patients with end-stage liver disease and are associated with significant morbidity and mortality. We…
2019 American Transplant Congress
Evidence to Support the Use of Kidney Allograft Function as a Clinical Trial Outcome Measure
M. Kadatz, J. Gill, S. Clark, J. S. Gill
Nephrology, University of British Columbia, Vancouver, BC, Canada
*Purpose: As a biomarker, kidney allograft function has been rejected as clinical trial outcome measure because it is not predictive of allograft survival. In this…
2019 American Transplant Congress
Dissecting The Role Of Donor Acute Kidney Injury On Molecular Responses Post-transplantation
S. Bontha¹, D. Maluf¹, E. Akalin², L. Gallon³, J. Eason⁴, V. Mas⁵
¹UTHSC, Memphis, TN, ²Albert Einstein Medical College, Bronx, NY, ³Northwestern University, Chicago, IL, ⁴Director of Transplantation, Memphis, TN, ⁵Director of Transplant Research, Memphis, TN
*Purpose: In the current scenario of shortage of donor organs, kidneys with AKI are being used and outcome research reports show that the outcomes could…
2019 American Transplant Congress
Panel Reactive Antibody Stratification as a Guide to Induction Selection in Deceased-Donor Kidney Transplantation: Impact of Clinical Practice on Outcomes
H. Ibrahim¹, J. Gregg¹, K. Alquadan¹, U. Akanit², K. L. Womer¹, A. H. Santos¹
¹Medicine, University of Florida, Gainesville, FL, ²Ubon Ratchathani University, Ubonratchathani, Thailand
*Purpose: We aimed to determine the outcomes associated with anti-thymocyte globulin (ATG), alemtuzumab (ALM) or interleukin-2 receptor antagonist (IL2-RA) induction in adult deceased-donor (DD) kidney…
2019 American Transplant Congress
Poor Practitioner Adherence to Clinical Tobacco Use Guidelines in Liver Transplant Recipients
M. Kosirog¹, P. T. Campbell¹, S. Montag², S. Connolly¹, A. Daud³, A. Das¹, S. Pine¹, D. Finn³, J. Levitsky¹, J. L. Holl⁴, D. Lloyd-Jones⁵, L. B. VanWagner⁶
¹Division of GI and Hepatology, Department of Medicine, Northwestern Medicine, Chicago, IL, ²Department of Preventive Medicine, Northwestern Medicine, Chicago, IL, ³Center for Healthcare Studies, Northwestern Medicine, Chicago, IL, ⁴Department of Pediatrics & Center for Healthcare Studies, Northwestern Medicine, Chicago, IL, ⁵Departments of Preventive Medicine and Medicine-Cardiology, Northwestern Medicine, Chicago, IL, ⁶Division of GI and Hepatology, Department of Medicine and Department of Preventive Medicine, Northwestern Medicine, Chicago, IL
*Purpose: Tobacco use is a modifiable risk factor for major adverse cardiovascular events (MACE) in liver transplant recipients (LTRs). However, data are lacking about practitioner…